Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461Sherif S. Farag, Clara D. Bloomfield, Mark J. Pettenati et al.|Blood|2006Cited by 332
Patients With t(8;21)(q22;q22) and Acute Myeloid Leukemia Have Superior Failure-Free and Overall Survival When Repetitive Cycles of High-Dose Cytarabine Are AdministeredJohn C. Byrd, Clara D. Bloomfield, Richard K. Dodge et al.|Journal of Clinical Oncology|1999Cited by 312
Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461.John C. Byrd, C. D. Bloomfield, R B Weiss et al.|Journal of Clinical Oncology|1997Cited by 236